EE200000285A - Keemilised ühendid - Google Patents

Keemilised ühendid

Info

Publication number
EE200000285A
EE200000285A EEP200000285A EEP200000285A EE200000285A EE 200000285 A EE200000285 A EE 200000285A EE P200000285 A EEP200000285 A EE P200000285A EE P200000285 A EEP200000285 A EE P200000285A EE 200000285 A EE200000285 A EE 200000285A
Authority
EE
Estonia
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
EEP200000285A
Other languages
English (en)
Estonian (et)
Inventor
Peter Charles Cousins Richard
David Eldred Colin
Cox Brian
Michael Kenneth Pennell Andrew
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of EE200000285A publication Critical patent/EE200000285A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200000285A 1997-11-08 1998-11-06 Keemilised ühendid EE200000285A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007021 WO1999024449A2 (fr) 1997-11-08 1998-11-06 Composes chimiques

Publications (1)

Publication Number Publication Date
EE200000285A true EE200000285A (et) 2001-08-15

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000285A EE200000285A (et) 1997-11-08 1998-11-06 Keemilised ühendid

Country Status (29)

Country Link
US (1) US6455510B1 (fr)
EP (2) EP1457495A1 (fr)
JP (1) JP2001522857A (fr)
KR (1) KR20010031875A (fr)
CN (1) CN1285843A (fr)
AP (1) AP2000001801A0 (fr)
AR (1) AR011229A1 (fr)
AT (1) ATE273990T1 (fr)
AU (1) AU2048399A (fr)
BR (1) BR9813976A (fr)
CA (1) CA2309200A1 (fr)
CO (1) CO5021135A1 (fr)
DE (1) DE69825780T2 (fr)
EA (1) EA200000392A1 (fr)
EE (1) EE200000285A (fr)
ES (1) ES2222621T3 (fr)
GB (1) GB9723589D0 (fr)
HR (1) HRP20000275A2 (fr)
HU (1) HUP0004082A2 (fr)
IL (1) IL135964A0 (fr)
IS (1) IS5477A (fr)
MA (1) MA26565A1 (fr)
NO (1) NO20002361L (fr)
PE (1) PE20000013A1 (fr)
PL (1) PL340921A1 (fr)
SK (1) SK6722000A3 (fr)
TR (1) TR200002131T2 (fr)
WO (1) WO1999024449A2 (fr)
ZA (1) ZA9810125B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0106867D0 (en) * 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
NZ532062A (en) 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
EP1375508A1 (fr) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH Dérivés de l'adénosine N6-substitués et leur utilisation comme médicament
US7265111B2 (en) * 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
RU2340623C2 (ru) * 2002-08-15 2008-12-10 Си Ви Терапьютикс, Инк. Частичные и полные агонисты аденозиновых рецепторов a1
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
JP2008512457A (ja) * 2004-09-09 2008-04-24 アメリカ合衆国 A3及びa1アデノシン受容体作用薬としてのプリン誘導体
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (fr) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Procede permettant de traiter l'anemie a hematies falciformes
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
RU2009115954A (ru) 2006-09-29 2010-11-10 Новартис АГ (CH) Пиразолопиримидины в качестве ингибиторов липидной киназы р13к
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
CN101938904A (zh) * 2008-01-09 2011-01-05 PGx健康有限责任公司 用a2ar激动剂鞘内治疗神经性疼痛
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
HRP20121006T1 (hr) 2009-01-29 2013-01-31 Novartis Ag Supstituirani benzimidazoli za lijeäśenje astrocitoma
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composes hydrazone heterocycliques et leurs utilisations pour traiter le cancer et l'inflammation
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (fr) 2009-08-20 2011-02-24 Novartis Ag Composes d'oximes heterocycliques
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
KR20140014184A (ko) 2011-02-25 2014-02-05 아이알엠 엘엘씨 Trk 억제제로서의 화합물 및 조성물
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AU2012310168B2 (en) 2011-09-15 2015-07-16 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013078440A2 (fr) 2011-11-23 2013-05-30 Intellikine, Llc Régimes de traitement améliorés utilisant des inhibiteurs de mtor
EP3964513A1 (fr) 2012-04-03 2022-03-09 Novartis AG Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
US12324807B2 (en) 2018-06-01 2025-06-10 Cornell University Combination therapy for PI3K-associated disease or disorder
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
AU2023393410A1 (en) 2022-12-16 2025-07-31 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
AU2022597A (en) * 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) * 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
GB9723589D0 (en) 1998-01-07
WO1999024449A3 (fr) 1999-08-19
AU2048399A (en) 1999-05-31
NO20002361D0 (no) 2000-05-05
IL135964A0 (en) 2001-05-20
PE20000013A1 (es) 2000-01-21
CN1285843A (zh) 2001-02-28
CA2309200A1 (fr) 1999-05-20
EP1030857A2 (fr) 2000-08-30
SK6722000A3 (en) 2001-01-18
KR20010031875A (ko) 2001-04-16
JP2001522857A (ja) 2001-11-20
PL340921A1 (en) 2001-03-12
ES2222621T3 (es) 2005-02-01
HUP0004082A2 (hu) 2001-04-28
CO5021135A1 (es) 2001-03-27
AR011229A1 (es) 2000-08-02
BR9813976A (pt) 2000-09-26
ATE273990T1 (de) 2004-09-15
IS5477A (is) 2000-05-03
TR200002131T2 (tr) 2001-01-22
EA200000392A1 (ru) 2000-12-25
AP2000001801A0 (en) 2000-06-30
MA26565A1 (fr) 2004-12-20
US6455510B1 (en) 2002-09-24
NO20002361L (no) 2000-07-05
ZA9810125B (en) 2000-05-05
HRP20000275A2 (en) 2000-12-31
EP1457495A1 (fr) 2004-09-15
WO1999024449A2 (fr) 1999-05-20
DE69825780D1 (de) 2004-09-23
DE69825780T2 (de) 2005-01-13
EP1030857B1 (fr) 2004-08-18

Similar Documents

Publication Publication Date Title
EE200000283A (et) Keemilised ühendid
EE200000284A (et) Keemilised ühendid
EE200000285A (et) Keemilised ühendid
ID15985A (id) Senyawa kimia
PT860428E (pt) Compostos pirimidiona
ID22850A (id) Senyawa-senyawa pirazina
IS5354A (is) Ný efnasambönd
NO994877D0 (no) Kalsilytiske forbindelser
ID20323A (id) Senyawa-senyawa triazinilaminostilbena
NO994900D0 (no) Forbindelser
FI972683A7 (fi) Kemiallisia yhdisteitä
DK100497A (da) Kemisk forbindelse
NO995404D0 (no) Forbindelser
EE9900602A (et) Ühendid
ID22983A (id) Senyawa-senyawa fluorometoksimino
NO995007D0 (no) Forbindelser
DE69737634D1 (de) Insektizide oxadiazinverbindungen
SE9601370L (sv) Kemisk förening
ITMI951259A0 (it) Composti chimici
ID18388A (id) Senyawa-senyawa heterosiklik
SE9701964D0 (sv) Compounds
SE9701397D0 (sv) Compounds
ID21202A (id) Senyawa heterosiklik
SE9702535D0 (sv) New compounds
SE9702746D0 (sv) New compounds